Oncology and Hematology

Episodes 113-128 of 485

Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- Jorge Nieva, MD
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Project Oncology®
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
- George Laliotis, MD, MPH, MHA
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Project Oncology®
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Global Oncology Academy
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
- Jacob Sands, MD
- Elaine Shum, MD
- Estelamari Rodriguez, MD, MPH
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Global Oncology Academy
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
- Lisa Newcomb, PhD
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Global Oncology Academy
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
- Lisa Newcomb, PhD
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Global Oncology Academy
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Global Oncology Academy
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Project Oncology®
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Project Oncology®
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Project Oncology®
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Wolff, MD
ADT Monotherapy for mHSPC: How to Identify the Right Patients
ADT Monotherapy for mHSPC: How to Identify the Right Patients
Global Oncology Academy
ADT Monotherapy for mHSPC: How to Identify the Right Patients
- Daniel J. George, MD
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Global Oncology Academy
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
- Daniel J. George, MD